Semi-Solid Dosage CDMO Market Outlook 2025-2030, with Lubrizol, Cambrex, Bora Pharmaceutical, Pierre Fabre, Piramal Pharma Solutions, DPT Laboratories, LGM Pharma, Pace Analytical Life Sciences & more - ResearchAndMarkets.com

DUBLIN --(BUSINESS WIRE)

The "Semi-Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Route of Administration (Topical, Transdermal), By Product, By Service, By End Use, By Region, And Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global semi-solid dosage CDMO market size is estimated to reach USD 67.4 billion by 2030, expanding at a CAGR of 11.90% from 2025 to 2030.

The global semi-solid dosage CDMO market size is driven due to growing trend towards personalized medicine coupled with increasing demand for innovative drug delivery systems. Patients prefer semi-solid formulations, such as creams, gels, and ointments, due to their ease of application and rapid absorption. Moreover, it has significant adoption for dermatological treatments to enhance patient treatment options. According to the data published by the American Academy of Dermatology Association in September 2024, Acne is the most common condition affecting approximately 50 million people in the U.S. annually. Moreover, 85% of the people are among age 12 to 24. Thus, increasing prevalence of skin disorders has led to an increasing demand for the development of topical formulations, consequently driving the demand for CDMOs to expand their capabilities in semi-solid dosage forms.

Furthermore, constant technological advancements in formulation and manufacturing processes have also propelled the semi-solid dosage market. Innovations such as nanotechnology and advanced emulsion techniques have improved the efficacy and stability of semi-solid formulations. These advancements enable CDMOs to produce high-quality products that meet stringent regulatory requirements, thereby attracting more clients. For instance, the development of nano-emulsions has enhanced the bioavailability of active ingredients, making semi-solid formulations more effective in treating various conditions, including chronic pain and inflammatory diseases.

In addition, increasing prevalence of chronic diseases, coupled with an aging population, is also contributing to the growth of the semi-solid dosage CDMO market. As more individuals seek treatments for conditions such as arthritis, diabetes, and skin disorders, the demand for effective semi-solid formulations is projected to increase in the coming years. This trend is particularly prominent in geriatric care, where semi-solid forms are often preferred due to their ease of use. Thus, these factors are further contributing to the market growth.

Semi-Solid Dosage CDMO Market Report Highlights

• Based on product, topical segment dominated in the market with a share of 88.53% in 2024. These formulations are particularly effective for localized treatments, making them ideal for dermatological applications
• Based on rout of administration, the creams and lotions segment dominated the semi-solid dosage CDMO industry with 42.49% share in 2024. These formulations offer unique benefits such as ease of application, pleasant texture, and enhanced skin absorption which is contributing to the segment's growth
• Based on service, the contract manufacturing segment accounted for the largest revenue share in 2024. Pharmaceutical companies are increasingly outsourcing their manufacturing processes to CDMOs to focus on core competencies such as research and development
• Based on end use, the pharmaceutical companies segment accounted for the largest revenue share in 2024 owing to the increasing demand for innovative therapeutic solutions which has resulted into the increasing investment by the companies for the development of new drugs
• North America dominated the market with a share of 41.37% in 2024. The increasing prevalence of chronic diseases and increasing demand for advanced therapeutic solutions in the region are propelling market expansion

Key Attributes:

Key Topics Covered:

Chapter 1. Research Methodology and Scope

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

Chapter 3. Semi-Solid Dosage CDMO Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.2. Market Dynamics

3.3. Semi-Solid Dosage CDMO Market Analysis Tools

3.3.1. Industry Analysis - Porter's

3.3.2. PESTEL Analysis

3.3.3. COVID-19 Impact Analysis

Chapter 4. Semi-Solid Dosage CDMO Market: Route of Administration Estimates & Trend Analysis

4.1. Route of Administration: Segment Dashboard

4.2. Semi-Solid Dosage CDMO Market, By Route of Administration: Movement Analysis

4.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Route of Administration, 2018 - 2030

4.4. Topical

4.5. Transdermal

4.6. Others

Chapter 5. Semi-Solid Dosage CDMO Market: Product Estimates & Trend Analysis

5.1. Product: Segment Dashboard

5.2. Semi-Solid Dosage CDMO Market, By Product: Movement Analysis

5.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Product, 2018 - 2030

5.4. Ointments

5.5. Creams and Lotions

5.6. Pastes

5.7. Gels

5.8. Others

Chapter 6. Semi-Solid Dosage CDMO Market: Service Estimates & Trend Analysis

6.1. Service: Segment Dashboard

6.2. Semi-Solid Dosage CDMO Market, By Service: Movement Analysis

6.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Service, 2018 - 2030

6.4. Contract Development

6.5. Contract Manufacturing

Chapter 7. Semi-Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

7.1. End Use: Segment Dashboard

7.2. Semi-Solid Dosage CDMO Market, By End Use: Movement Analysis

7.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030

7.4. Pharmaceutical Companies

7.5. Biopharmaceutical Companies

Chapter 8. Semi-Solid Dosage CDMO Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2030

8.2. Regional Market Dashboard

Chapter 9. Competitive Landscape

9.1. Company Categorization

9.2. Company Market Share Analysis, 2024

9.3. Company Profiles

• The Lubrizol Corporation
• Cambrex Corporation
• Contract Pharmaceuticals
• Bora Pharmaceutical
• Ascendia Pharmaceuticals
• Pierre Fabre group
• Piramal Pharma Solutions
• DPT Laboratories
• LGM Pharma
• Pace Analytical Life Sciences

For more information about this report visit https://www.researchandmarkets.com/r/qpxbhy

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250314539364/en/

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Copyright Business Wire 2025

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]